Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722239 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Hard CopyAdd to Basket



The US Drug Approval Trends and Yearbook 2008/2009
Cambridge Healthtech Institute, July 2008, Pages: 200


  Description  
    
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

The US Drug Approval Trends and Yearbook 2008/2009

The Largest Compendium of Drug Approval Performance Metrics Ever Compiled!

Finally a comprehensive source for the very latest performance metrics and trend analysis on every key aspect of the new drug approval process--The US Drug Approval Trends and Yearbook 2008/2009!

Building on last year's widely read edition, the new 2008/2009 edition examines hundreds of key trends and metrics to provide industry with all-new benchmarks and metrics on which to assess their own performance, to plan their own R&D projects, and to assess the various drug approval options and strategies available to them.

The US Drug Approval Trends and Yearbook 2008/2009 provides an unprecedented number of in-depth analyses and benchmarks, including the following:

- NDA and NME first-cycle success rates, review outcomes, and trends
- Complete review and approval profiles for each NME and NDA, including cycles to approval, review times, and review outcomes
- Analysis of drug review times, review cycle outcomes and success rates by therapeutic category and standard vs. priority classification
- NDA and NME cycles to approval and review times through mid-2006
- The impact of priority review, fast track, accelerated approval, orphan drug status and related programs on review times and review outcomes

Review outcomes, review times, and success rates for other key new drug submissions, including NDA resubmissions, efficacy supplements, and manufacturing supplements

Based on data compiled through internal studies, Freedom of Information requests to the FDA, and other public and private sources, our proprietary analyses will provide you with unique insights, benchmarks, and performance metrics in areas critical to the success of your R&D projects. We guarantee it!

Product samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

The US Drug Approval Trends and Yearbook 2006/2007

Bio/Pharma R&D Statistical Sourcebook 2008/2009

Project Finance Yearbook 2008/2009

Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response

New Drug Approval in the United States

Drugs: From Discovery to Approval, 2nd Edition

Transfer Pricing Review 2008/2009

International Financial Centres' Yearbook 2008/2009

New Drug Approval in Japan

Transportation Finance Review 2008/2009

International Real Estate Finance Review 2008/2009

What to Know Before Approaching the Food and Drug Administration (FDA) for Approval: 50 Minute ReedLogic Video Enabling You to Get Executive Smart on the Latest Trends and Best Practices for Success



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds